Elevated Serum Amyloid a Levels Are not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype

Autor: Jan C. Grutters, Claudia Roodenburg-Benschop, Bob Meek, Marcel Veltkamp, Milou C. Schimmelpennink, Els Beijer
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
0301 basic medicine
medicine.medical_specialty
animal diseases
Gene Expression
Gastroenterology
Article
Cohort Studies
Pathogenesis
03 medical and health sciences
Idiopathic pulmonary fibrosis
0302 clinical medicine
Fibrosis
Internal medicine
hemic and lymphatic diseases
Eosinophilic
medicine
Humans
Serum amyloid A
sarcoidosis
lcsh:QH301-705.5
Aged
Serum Amyloid A Protein
business.industry
fibrosis
Granulomatosis with Polyangiitis
General Medicine
Middle Aged
medicine.disease
Idiopathic Pulmonary Fibrosis
Infliximab
SAA
stomatognathic diseases
C-Reactive Protein
Methotrexate
030104 developmental biology
lcsh:Biology (General)
030228 respiratory system
Case-Control Studies
Prednisone
Female
Sarcoidosis
business
Granulomatosis with polyangiitis
Immunosuppressive Agents
Hypersensitivity pneumonitis
Alveolitis
Extrinsic Allergic
Zdroj: Cells
Volume 10
Issue 3
Cells, Vol 10, Iss 585, p 585 (2021)
ISSN: 2073-4409
DOI: 10.3390/cells10030585
Popis: Elevated Serum Amyloid A (SAA) levels have been found in several inflammatory diseases, including sarcoidosis. SAA is suggested to be involved in sarcoidosis pathogenesis by involvement in granuloma formation and maintenance. We hypothesized that SAA serum levels would be higher in sarcoidosis compared to other non-infectious granulomatous and non-granulomatous diseases. SAA levels were measured in serum from sarcoidosis, Hypersensitivity pneumonitis (HP), and (eosinophilic) granulomatosis with polyangiitis ((E)GPA) patients. Idiopathic pulmonary fibrosis (IPF) patients were included as non-granulomatous disease group. SAA levels of patients with sarcoidosis (31.0 µg/mL), HP (23.4 µg/mL), (E)GPA (36.9 µg/mL), and IPF (22.1 µg/mL) were all higher than SAA levels of healthy controls (10.1 µg/mL). SAA levels did not differ between the diagnostic groups. When SAA serum levels were analyzed in sarcoidosis subgroups, fibrotic sarcoidosis patients showed higher SAA levels than sarcoidosis patients without fibrosis (47.8 µg/mL vs. 29.4 µg/mL, p = 0.005). To conclude, the observation that fibrotic sarcoidosis patients have higher SAA levels, together with our finding that SAA levels were also increased in IPF patients, suggests that SAA may next to granulomatous processes also reflect the process of fibrogenesis. Further studies should clarify the exact role of SAA in fibrosis and the underlying mechanisms involved.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje